Tango Therapeutics Inc at Barclays Global Healthcare Conference Transcript
Good afternoon, everyone. Welcome to Barclays Global Healthcare Conference in Miami. Do raise a hand or e-mail me or my team if you have questions. And my name is Peter Lawson, I'm one of the biotech analysts at Barclays and I cover smid-cap biotech, focusing mostly on oncology. I'm really delighted to have up on stage with us the CEO from Tango Therapeutics that's Barbara Weber.
Questions & Answers
And I guess the first question really is around PRMT5 inhibitors, the MTA cooperative. Where do you see the differentiation emerging through the year for your molecule versus the others? Or is there anything to be said about that?
Yeah. Well, I think the big news for this year is there's going to be the emergence of data from the three MTA cooperative PRMT5 inhibitors. Of course, that's us, Tango, Amgen, and Mirati. And I think the differentiation remains to be seen.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
